ReviewWorld journal of gastroenterology2014
CYP2C19 polymorphism influences Helicobacter pylori eradication.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05664685 (Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Effects of CYP2C19 genetic polymorphisms on the cure rates ofFrontiers in pharmacology · 2022Pooled it
- AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.Gastroenterology · 2021Guideline
- High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.Scientific reports · 2019Pooled it
- Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens forWorld journal of gastroenterology · 2025Trial
- Amoxicillin high-dose dual therapy forWorld journal of gastroenterology · 2025Trial
- LOW-NICKEL DIET AS A STRATEGY IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2025Trial
- Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).Scientific reports · 2024Trial
- Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.Journal of gastroenterology · 2023Trial
- Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).PloS one · 2023Trial
- Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.Advances in therapy · 2021Trial
- Application of Visual Gene Clip-Based Tailored Therapy for the Eradication ofBioMed research international · 2021Trial
- The Association betweenGenes · 2020Trial
- Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.Clinical and experimental medicine · 2018Trial
- Trial
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026Article
- Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy forAnnals of medicine · 2025Article
- Effectiveness of Susceptibility-Guided Therapy forInfection and drug resistance · 2025Article
- Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy forGastro hep advances · 2025Review
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The known factors that have contributed to the decline of Helicobacter pylori (H. pylori) eradication rate include antibiotic resistance, poor compliance, high gastric acidity, high bacterial load, and cytochrome P450 2C19 (CYP2C19) polymorphism. Proton pump inhibitor (PPI) is important in the eradication regimen. The principal enzyme implicated in the metabolism of PPIs is CYP2C19. The effects of PPI depend on metabolic enzyme, cytochrome P450 enzymes, and CYP2C19 with genetic differences in the activity of this enzyme (the homozygous EM, heterozygous EM (HetEM), and poor metabolizer). The frequency of the CYP2C19 polymorphism is highly varied among different ethnic populations. The CYP2C19 genotype is a cardinal factor of H. pylori eradication in patients taking omeprazole- based or lansoprazole-based triple therapies. In contrast, the CYP2C19 polymorphism has no significant effect on the rabeprazole-based or esomeprazole-based triple therapies. The efficacy of levofloxacin-based rescue triple therapy might be also affected by the CYP2C19 polymorphism, but CYP2C19 genotypes did not show obvious impact on other levofloxacin-based rescue therapies. Choice of different PPIs and/or increasing doses of PPIs should be individualized based on the pharmacogenetics background of each patient and pharmacological profile of each drug. Other possible factors influencing gastric acid secretion (e.g., IL-1β- 511 polymorphism) would be also under consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.